Sentiment-Signal
9,0
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Unternehmen & Branche
| Name | AGIOS PHARMACEUTICALS, INC. |
|---|---|
| Ticker | AGIO |
| CIK | 0001439222 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,44 Mrd. USD |
| Beta | 0,79 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 54,028,000 | -412,781,000 | -7.12 | 1,297,225,000 | 1,193,114,000 |
| 2025-09-30 | 10-Q | 12,880,000 | -103,433,000 | -1.78 | 1,385,705,000 | 1,284,330,000 |
| 2025-06-30 | 10-Q | 12,455,000 | -112,020,000 | -1.93 | 1,471,237,000 | 1,369,555,000 |
| 2025-03-31 | 10-Q | 8,726,000 | -89,289,000 | -1.55 | 1,555,518,000 | 1,466,528,000 |
| 2024-12-31 | 10-K | 36,498,000 | 673,725,000 | 11.64 | 1,663,199,000 | 1,540,956,000 |
| 2024-09-30 | 10-Q | 8,964,000 | 947,915,000 | 16.22 | 1,791,794,000 | 1,626,672,000 |
| 2024-06-30 | 10-Q | 8,615,000 | -96,118,000 | -1.69 | 773,063,000 | 660,510,000 |
| 2024-03-31 | 10-Q | 8,189,000 | -81,549,000 | -1.45 | 849,709,000 | 743,922,000 |
| 2023-12-31 | 10-K | 26,823,000 | -352,088,000 | -6.33 | 937,118,000 | 811,019,000 |
| 2023-09-30 | 10-Q | 7,399,000 | -91,324,000 | -1.64 | 1,007,258,000 | 886,843,000 |
| 2023-06-30 | 10-Q | 6,712,000 | -83,806,000 | -1.51 | 1,085,153,000 | 964,236,000 |
| 2023-03-31 | 10-Q | 5,609,000 | -81,018,000 | -1.47 | 1,151,298,000 | 1,036,526,000 |
| 2022-12-31 | 10-K | 14,240,000 | -231,801,000 | -4.23 | 1,238,718,000 | 1,100,814,000 |
| 2022-09-30 | 10-Q | 3,516,000 | -81,747,000 | -1.49 | 1,180,320,000 | 1,050,170,000 |
| 2022-06-30 | 10-Q | 5,582,000 | -91,806,000 | -1.68 | 1,252,467,000 | 1,124,070,000 |
| 2022-03-31 | 10-Q | 832,000 | -94,774,000 | -1.74 | 1,335,859,000 | 1,207,453,000 |
| 2021-12-31 | 10-K | 0 | 1,604,715,000 | -1.74 | 1,437,736,000 | 1,291,975,000 |
| 2021-09-30 | 10-Q | 0 | -88,766,000 | -1.56 | 1,541,498,000 | 1,394,762,000 |
| 2021-06-30 | 10-Q | 0 | -86,217,000 | -1.41 | 1,874,603,000 | 1,721,816,000 |
| 2021-03-31 | 10-Q | 0 | 1,874,325,000 | 26.95 | 2,488,434,000 | 2,296,630,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -3,280 | 34.71 | -113,848.80 | -106,2% | |
| 2026-04-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -3,141 | 34.71 | -109,024.11 | -101,7% | |
| 2026-03-05 | Viswanadhan Krishnan | Officer, Chief Corp Dev & Strategy | Open Market Sale | -2,959 | 27.80 | -82,260.20 | -76,7% | |
| 2026-03-03 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -5,272 | 28.88 | -152,255.36 | -142,0% | |
| 2026-03-02 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -3,870 | 28.96 | -112,075.20 | -104,6% | |
| 2026-03-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -1,573 | 28.96 | -45,554.08 | -42,5% | |
| 2026-03-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -1,187 | 28.96 | -34,375.52 | -32,1% | |
| 2026-03-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -594 | 28.96 | -17,202.24 | -16,0% | |
| 2026-03-02 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -1,681 | 28.96 | -48,681.76 | -45,4% | |
| 2026-03-02 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -1,187 | 28.96 | -34,375.52 | -32,1% | |
| 2026-03-02 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -1,163 | 28.96 | -33,680.48 | -31,4% | |
| 2026-03-02 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -1,681 | 28.96 | -48,681.76 | -45,4% | |
| 2026-03-02 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -727 | 28.96 | -21,053.92 | -19,6% | |
| 2026-03-02 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -698 | 28.96 | -20,214.08 | -18,9% | |
| 2026-03-02 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -1,681 | 28.96 | -48,681.76 | -45,4% | |
| 2026-03-02 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -1,187 | 28.96 | -34,375.52 | -32,1% | |
| 2026-03-02 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -1,681 | 28.96 | -48,681.76 | -45,4% | |
| 2026-03-02 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -1,187 | 28.96 | -34,375.52 | -32,1% | |
| 2026-03-02 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -8,267 | 28.96 | -239,412.32 | -223,4% | |
| 2026-03-02 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -5,918 | 28.96 | -171,385.28 | -159,9% | |
| 2026-03-02 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -798 | 28.96 | -23,110.08 | -21,6% | |
| 2026-01-05 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -2,872 | 27.02 | -77,601.44 | -72,4% | |
| 2025-12-30 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -2,932 | 27.09 | -79,427.88 | -74,1% | |
| 2025-12-30 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -6,230 | 27.09 | -168,770.70 | -157,5% | |
| 2025-12-30 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -12,473 | 27.09 | -337,893.57 | -315,2% | |
| 2025-12-30 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -2,932 | 27.09 | -79,427.88 | -74,1% | |
| 2025-12-30 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -2,932 | 27.09 | -79,427.88 | -74,1% | |
| 2025-12-30 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -2,932 | 27.09 | -79,427.88 | -74,1% | |
| 2025-11-12 | Scadden David | Director | Open Market Sale | -200 | 43.84 | -8,768.00 | -8,2% | |
| 2025-11-11 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -2,454 | 43.78 | -107,436.12 | -100,2% | |
| 2025-10-30 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -200 | 43.81 | -8,762.00 | -8,2% | |
| 2025-10-27 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -3,302 | 43.92 | -145,023.84 | -135,3% | |
| 2025-10-08 | Scadden David | Director | Open Market Sale | -200 | 41.00 | -8,200.00 | -7,7% | |
| 2025-09-30 | Scadden David | Director | Open Market Sale | -200 | 40.00 | -8,000.00 | -7,5% | |
| 2025-09-26 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -3,651 | 36.77 | -134,247.27 | -125,2% | |
| 2025-09-05 | Washburn Theodore James Jr. | Officer, Principal Accounting Officer | Open Market Sale | -8,546 | 36.87 | -315,091.02 | -294,0% | |
| 2025-08-27 | Scadden David | Director | Open Market Sale | -200 | 40.00 | -8,000.00 | -7,5% | |
| 2025-08-08 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -11,085 | 36.67 | -406,486.95 | -379,2% | |
| 2025-07-10 | Scadden David | Director | Open Market Sale | -1,400 | 40.00 | -56,000.00 | -52,2% | |
| 2025-07-09 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -847 | 38.76 | -32,829.72 | -30,6% | |
| 2025-07-09 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -11,067 | 37.93 | -419,771.31 | -391,6% | |
| 2025-07-01 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -4,091 | 34.17 | -139,789.47 | -130,4% | |
| 2025-06-24 | Gheuens Sarah | Officer, Chief Medical Officer | Open Market Sale | -2,909 | 33.54 | -97,567.86 | -91,0% | |
| 2025-06-24 | Burns James William | Officer, Chief Legal Officer | Open Market Sale | -2,799 | 33.54 | -93,878.46 | -87,6% | |
| 2025-06-24 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -12,471 | 33.54 | -418,277.34 | -390,2% | |
| 2025-06-24 | Goff Brian | Director, Officer, Chief Executive Officer | Open Market Sale | -6,229 | 33.54 | -208,920.66 | -194,9% | |
| 2025-06-24 | Milanova Tsveta | Officer, Chief Commercial Officer | Open Market Sale | -2,770 | 33.54 | -92,905.80 | -86,7% | |
| 2025-06-24 | Jones Cecilia | Officer, Chief Financial Officer | Open Market Sale | -1,780 | 33.54 | -59,701.20 | -55,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.